Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Celecoxib/famciclovir - Dogwood Therapeutics

Next Previous
Drug Profile

Celecoxib/famciclovir - Dogwood Therapeutics

Alternative Names: Famciclovir/celecoxib; IMC-1

Latest Information Update: 04 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Med Concepts
  • Developer Dogwood Therapeutics
  • Class Antimigraines; Antineoplastics; Antipyretics; Antirheumatics; Antivirals; Irritable bowel syndrome therapies; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Nucleosides; Purines; Pyrazoles; Small molecules; Sulfonamides
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; DNA-directed DNA polymerase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Fibromyalgia
  • Phase I Irritable bowel syndrome
  • No development reported Chronic fatigue syndrome

Most Recent Events

  • 04 May 2026 Celecixib/famciclovir is still in phase-I development in Irritable-bowel-syndrome in Unknown (PO) (Virios Therapeutics pipeline, May 2026)
  • 23 Apr 2026 PridCor Therapeutics in-licenses Celecoxib/famciclovir from Dogwood Therapeutics
  • 13 Nov 2024 Celecoxib/famciclovir - Dogwood Therapeutics is available for licensing as of 07 Nov 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top